Clene (CLNN) Financials

Clene’s latest financial statements show a company that remains in an early commercial or development stage. Revenue improved in the second quarter of 2026, but operating expenses and non-operating losses continued to overwhelm sales. The balance sheet also remains highly leveraged, while recent equity issuances have provided much-needed cash at the cost of shareholder dilution.

• Revenue increased sequentially. Q2 2026 revenue rose to $90,000 from $15,000 in Q1 2026 and $27,000 in the restated Q2 2025 results. Gross profit increased to $54,000, although the gross margin declined to 60% from 100% in the prior two comparable quarters.
• Operating cash burn improved in the latest quarter. Net cash used in operating activities declined to $2.6 million in Q2 2026 from $4.5 million in Q1 2026 and $4.7 million in Q2 2025. This improvement was partly supported by a $4.8 million favorable change in operating assets and liabilities.
• Financing activity increased cash reserves. Clene raised $6.4 million through common equity issuance during Q2 2026, producing $6.3 million of net financing cash flow. Cash and equivalents increased to $9.7 million at June 30, 2026, from $5.9 million at the end of Q1.
• Near-term liquidity is better than the company’s negative equity position might suggest. Current assets of $14.9 million exceeded current liabilities of $4.9 million, implying a current ratio of roughly 3.1. This provides some cushion for near-term obligations, although it does not resolve the company’s longer-term funding needs.
• Research and development spending remains substantial. R&D expense rose to $3.5 million in Q2 2026 from $329,000 in Q1, while remaining broadly comparable with the $3.5 million reported in Q2 2025. The spending could support future product development, but it has not yet translated into meaningful revenue or profitability.
• Other income and expense has been volatile. Net other expense was $7.4 million in Q2 2026, compared with $5.3 million in Q1 and $938,000 in Q2 2025. These large fluctuations make reported earnings less predictable and complicate efforts to assess the company’s underlying operating performance.
• Losses remain significant and worsened sequentially. Net loss increased to $13.4 million, or $1.08 per basic share, in Q2 2026 from $8.1 million, or $0.69 per share, in Q1. Clene has reported substantial quarterly losses throughout the supplied period, with only modest revenue relative to its cost structure.
• Operating expenses remain far above revenue. Total operating expenses were $5.4 million in Q2 2026 against just $90,000 of revenue. This produced an operating loss of $5.3 million and indicates that Clene would need a substantial increase in sales, a reduction in spending, or both to approach operating breakeven.
• The balance sheet shows negative shareholders’ equity. Total liabilities reached $47.8 million versus $23.0 million of assets, resulting in negative total equity of $24.8 million. Retained earnings were negative $329.8 million, reflecting the company’s accumulated losses.
• Clene remains dependent on external financing and shareholder dilution. Operating cash flow was still negative in Q2, while total debt, capital lease obligations and other noncurrent liabilities were substantial. Weighted-average basic shares increased to 12.4 million in Q2 2026 from 9.9 million in Q4 2025, and common stock increased by $7.5 million from Q1, indicating that equity financing is an important source of liquidity but may dilute existing investors.

Overall, the statements show modest revenue progress and lower operating cash burn in Q2 2026, but these improvements are outweighed by persistent losses, limited commercial revenue, negative equity and continued reliance on equity financing. Investors should closely monitor revenue growth, operating cash usage, the composition of other expenses and whether future financing can be secured without significant additional dilution.